Generalized Myasthenia Gravis (gMG) - Pipeline Insight, 2024

This Generalized Myasthenia Gravis (g MG) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Myasthenia Gravis (gMG) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in thisspace.

Geography Covered

• Global coverage

Generalized Myasthenia Gravis (g MG)Understanding

Generalized myasthenia gravis (GMG) is a neuromuscular transmission disorder that creates a fluctuating weakness of the voluntary muscles.

Myasthenia gravis (MG) is a disorder of neuromuscular transmission in which autoantibodies bind to acetylcholine receptors that are found in the postsynaptic membrane in the neuromuscular junction, making it difficult to transmit impulses to skeletal muscles and causing weakness. Its prevalence varies between 15 to 179 cases per million and the mortality rate varies between 0.06 to 0.89 per million person-years. This disease is characterized by fluctuating weakness of the voluntary muscles, which worsens with activity and as the day progresses. It is classified as generalized or as ocular.

Generalized Myasthenia Gravis (g MG) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Myasthenia Gravis (gMG) pipeline landscape is provided which includes the disease overview and Generalized Myasthenia Gravis (gMG) treatment guidelines. The assessment part of the report embraces, in depth Generalized Myasthenia Gravis (gMG) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Myasthenia Gravis (gMG) collaborations, licensing, mergers and acquisition, funding, designations and other product relateddetails.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Generalized Myasthenia Gravis (g MG). The therapies under development are focused on novel approaches to treat/improve Generalized Myasthenia Gravis(gMG).

Generalized Myasthenia Gravis (g MG) EmergingDrugs

Nipocalimab: Prevention Bio
Momenta has developed nipocalimab (M281), a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody. In patients with g MG, nipocalimab is expected to improve nerve-to-muscle signals and muscle function, thus alleviating the clinical signs and symptoms of gMG. Nipocalimab has been granted Fast Track and Orphan Drug designation by the FDA in thisindication.

Generalized Myasthenia Gravis (g MG): TherapeuticAssessment

This segment of the report provides insights about the Generalized Myasthenia Gravis (g MG) drugs segregated based on following parameters that define the scope of the report, suchas:

Major Players in Generalized Myasthenia Gravis (gMG)

There are approx. 10+ key companies which are developing the therapies Generalized Myasthenia Gravis (g MG). The companies which have their Generalized Myasthenia Gravis (gMG) drug candidates in the most advanced stage, i.e preregistration includeRoche

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Generalized Myasthenia Gravis (g MG) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs suchas

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Generalized Myasthenia Gravis (g MG): Pipeline DevelopmentActivities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Myasthenia Gravis (g MG) therapeutic drugs key players involved in developing keydrugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Myasthenia Gravis (g MG)drugs.

Generalized Myasthenia Gravis (g MG) ReportInsights

• Generalized Myasthenia Gravis (g MG)Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Generalized Myasthenia Gravis (g MG) ReportAssessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Generalized Myasthenia Gravis (g MG)drugs?
• How many Generalized Myasthenia Gravis (g MG) drugs are developed by eachcompany?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Myasthenia Gravis (gMG)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Generalized Myasthenia Gravis (g MG)therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Generalized Myasthenia Gravis (g MG) and theirstatus?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biocon
• Cartesian Therapeutics
• UCB
• Momenta Pharamaceuticals
• HanAll Biopharma
• Roche
• Alexion
• Novartis
• Takeda
• BioMarin

Key Products

• Descartes 08
• Zilucoplan
• Nipocalimab
• Rozanolixizumab
• Batoclimab
• Satralizumab
• Vemircopan
• Iscalimab
• Mezagitamab
• Amifampridine

This product will be delivered within 2 business days.